Management Options for Node-Positive Muscle-Invasive Bladder Cancer

被引：0
|
作者：
Polimera, V. [1 ]
Bhatia, Priyanka [1 ]
Wheelden, Megan [1 ]
Perimbeti, Stuthi [1 ]
Warrick, Joshua [2 ]
Joshi, Monika [1 ]
Joshi, Monika [1 ]
机构：
[1] Penn State Canc Inst, Dept Med, Div Hematol Oncol, Hershey, PA USA
[2] Penn State Hershey Med Ctr, Dept Pathol, Hershey, PA USA
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2024年 / 22卷 / 08期
关键词：
Biomarker; chemotherapy; immunotherapy; node-positive muscle-invasive bladder cancer; radiation; METASTATIC UROTHELIAL CARCINOMA; CISPLATIN-INELIGIBLE PATIENTS; ADJUVANT CHEMOTHERAPY; OPEN-LABEL; NEOADJUVANT CHEMOTHERAPY; RADICAL CYSTECTOMY; SINGLE-ARM; TRANSURETHRAL SURGERY; MULTICENTER; THERAPY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Localized node-positive bladder cancer is characterized by a high degree of heterogeneity, leading to significant variability in overall survival outcomes among affected individuals. The absence of standardized treatment guidelines presents a critical challenge in managing these patients effectively. This comprehensive review article delves into the pathophysiology, clinical significance, and management of node-positive bladder cancer. It critically evaluates the current therapeutic landscape and explores emerging treatment strategies, including novel drugs currently undergoing clinical trials. By synthesizing the latest research findings, the review aims to provide valuable insights into the optimal management of node-positive urothelial cell carcinoma, ultimately contributing to improved patient outcomes and quality of life.
引用
收藏
页码：392 / 402
页数：11
相关论文
共 50 条
  • [41] Surgical bladder-preserving techniques in the management of muscle-invasive bladder cancer
    Lyons, Matthew D.
    Smith, Angela B.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (06) : 262 - 270
  • [42] Prognosis of node-positive bladder cancer in 2016
    Van Bruwaene, Siska
    Costello, Anthony J.
    Van Poppel, Hendrik
    MINERVA UROLOGICA E NEFROLOGICA, 2016, 68 (02) : 125 - 137
  • [43] Bladder only versus bladder plus pelvic lymph node chemoradiation for muscle-invasive bladder cancer
    Patel, Sagar A.
    Liu, Yuan
    Solanki, Abhishek A.
    Baumann, Brian C.
    Efstathiou, Jason A.
    Jani, Ashesh B.
    Chang, Albert J.
    Fischer-Valuck, Benjamin
    Royce, Trevor J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (07) : 325.e15 - 325.e23
  • [44] Bladder preserving strategies for muscle-invasive bladder cancer
    Merseburger, Axel S.
    Matuschek, Ira
    Kuczyk, Markus A.
    CURRENT OPINION IN UROLOGY, 2008, 18 (05) : 513 - 518
  • [45] Which Biomarkers are Useful in the Management of Muscle-invasive Bladder Cancer in 2022?
    Szymaniak, Julie
    Porten, Sima P.
    EUROPEAN UROLOGY FOCUS, 2022, 8 (04): : 901 - 903
  • [46] Impact of neoadjuvant chemotherapy on therapeutic management of muscle-invasive bladder cancer
    Meyer, V.
    Flechon, A.
    Tartas, S.
    Fassi-Fehri, H.
    Ruffion, A.
    Martin, X.
    Colombel, M.
    PROGRES EN UROLOGIE, 2015, 25 (02): : 83 - 89
  • [47] Management of muscle-invasive bladder cancer in Victoria, 1990-1995
    Millar, JL
    Frydenberg, M
    Toner, G
    Syme, R
    Thursfield, V
    Giles, GG
    ANZ JOURNAL OF SURGERY, 2006, 76 (03) : 113 - 119
  • [48] Systemic, perioperative management of muscle-invasive bladder cancer and future horizons
    Funt, Samuel A.
    Rosenberg, Jonathan E.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (04) : 221 - 234
  • [49] Superficial and muscle-invasive bladder cancer: Principles of management for outcomes assessments
    Parekh, Dipen J.
    Bochner, Bernard H.
    Dalbagni, Guido
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (35) : 5519 - 5527
  • [50] Systemic, perioperative management of muscle-invasive bladder cancer and future horizons
    Samuel A. Funt
    Jonathan E. Rosenberg
    Nature Reviews Clinical Oncology, 2017, 14 : 221 - 234
12345